Source: Annual Congress 2001 - Mycobacterial susceptibility
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. M. Middleton, M. V. Chadwick, A. G. Nicholson, A. Dewar, R. K. Groger, E. J. Brown, T. L. Ratliff, R. Wilson (London, United Kingdom; St Louis, San Francisco, Iowa, United States Of America). Investigation of the inhibition of adherence of Mycobacterium avium complex (MAC) and Mycobacterium tuberculosis (MTB) to the respiratory mucosa. Eur Respir J 2001; 16: Suppl. 31, 3219

Member's Comments

No comment yet.

Related content which might interest you: Infection of the respiratory mucosa by Mycobacterium avium complex (MAC), Mycobacterium tuberculosis (MTB) and Mycobacterium smegmatis (MS) Source: Eur Respir J 2001; 18: Suppl. 33, 308s Year: 2001 Mycobacterium avium complex infection: phenotypes and outcomes Source: Eur Respir J, 50 (3) 1701380; 10.1183/13993003.01380-2017 Year: 2017 Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Clinical relevance of differentiation between Mycobacterium avium and M. intracellulare in M. avium complex pulmonary disease in Croatia Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005 Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012 Invasive Mycobacterium avium intracellulare infection Source: Eur Respir J 2006; 28: Suppl. 50, 312s Year: 2006 Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA Source: Eur Respir J 2013; 42: 454-460 Year: 2013 The spectrum of drug susceptibility of slow-growing nontuberculous mycobacteria (MAC, M. kansasii, M. xenopi) Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Isolation of M. abscessus from patients with M. avium complex (MAC) lung disease Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013 On the nature of Mycobacterium tuberculosis-latent bacilli Source: Eur Respir J 2004; 24: 1044-1051 Year: 2004 Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017 Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002 Clinical analysis of pulmonary Mycobacterium avium complex disease in Japan Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022 Antibody testing for Mycobacterium avium complex infection in cystic fibrosis patients Source: International Congress 2018 – Cystic fibrosis: microbiological aspects and new treatments Year: 2018 Mycobacterium tuberculosis (MTB) content in the air of in-patient facility for the management of pulmonary tuberculosis (TB) Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Mycobacterium abscessus respiratory infection: importance in immunosuppressed patients Source: Annual Congress 2008 - Lung and bone marrow transplantation: miscellaneous Year: 2008 Nontuberculous mycobacterial infections Source: Eur Respir Mon 2011; 52: 115-129 Year: 2011 Biological properties of Mycobacterium tuberculosis (Mtb) resistant to biocides Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021